Addario Lung Cancer Medical Institute (ALCMI)
LightNews LightNews
banner
alcmi.bsky.social
Addario Lung Cancer Medical Institute (ALCMI)
@alcmi.bsky.social
150 followers 260 following 320 posts
The Addario Lung Cancer Medical Institute (ALCMI) is a non-profit international consortium comprised of over 25 of the world's premier oncology research institutions. We fund and support investigator-led lung cancer clinical trials.
Posts Replies Media Videos
alcmi.bsky.social
The FDA has cleared the IND application for ILKN421H (STI-7349), a novel mRNA-based IL-2 variant from iLeukon Therapeutics, to advance into phase 2 studies in advanced non–small cell lung cancer. #lungcancer
www.cancernetwork.com/view/fda-cle...
FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC | CancerNetwork
ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.
www.cancernetwork.com
November 11, 2025 at 3:03 PM
alcmi.bsky.social
Wow! The American Lung Association Research Institute has committed $22 million to lung disease and lung cancer research, an unprecedented investment during a year of federal funding instability. #lungcancer
www.lung.org/media/press-...
Lung Association Steps Up with $22 Million in Research Funding as Federal Support for Science Wavers
Today, the American Lung Association Research Institute announced it has invested $22 million in new research grants, clinical research and strategic partnerships to advance the understanding,…
www.lung.org
November 10, 2025 at 3:03 PM
alcmi.bsky.social
A shift in the first-line management of EGFR-mutated non–small cell lung cancer (NSCLC) is upon us, according to Anastasios Dimou, M.D., and Aaron Mansfield, M.D., in their editorial published in NEJM Group. #lungcancer
www.nejm.org/doi/full/10....
EGFR-Mutated Lung Cancer — Letting the Butterfly Out of the Cocoon | NEJM
Somatic mutations in EGFR (epidermal growth factor receptor) account for approximately one third of lung cancer cases worldwide.1 A point mutation in exon 21 (L858R) or a short deletion in exon 19 ...
www.nejm.org
November 9, 2025 at 3:01 PM
alcmi.bsky.social
New study alert! The DESTINY-Lung06 phase 3 trial has officially launched, marking the first global study to evaluate ENHERTU (trastuzumab deruxtecan) plus pembrolizumab as a first-line treatment for HER2 overexpressing metastatic non-squamous NSCLC. #lungcancer
finance.yahoo.com/news/destiny...
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J., October 31, 2025--DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC
finance.yahoo.com
November 8, 2025 at 3:01 PM
alcmi.bsky.social
If you have a clinical trial idea, we're here to help you get it off the ground. #lungcancer
alcmi.org/researcher-p...
Partner with ALCMI to Drive Lung Cancer Research Forward
Explore ALCMI’s Researcher Portal for tools, funding, and collaboration opportunities that empower investigator-initiated lung cancer clinical trials and breakthrough discoveries.
alcmi.org
November 7, 2025 at 3:03 PM
alcmi.bsky.social
Frozen section pathology improves intraoperative decision-making in early-stage lung cancer surgery, according to new research from Mayo Clinic thoracic surgeons and pulmonary pathologists. #lungcancer
www.mayoclinic.org/medical-prof...
Frozen section pathology enhances intraoperative decision-making in early-stage lung cancer surgery - Mayo Clinic
Nov. 01, 2025
www.mayoclinic.org
November 6, 2025 at 3:04 PM
alcmi.bsky.social
Pafolacianine has advanced the surgical resection of early-stage non-small cell lung cancer, enabling surgeons to detect and remove lesions previously missed by conventional techniques. #lungcancer
www.mayoclinic.org/medical-prof...
New drug helps Mayo Clinic surgeons detect smaller lesions with greater accuracy during lung cancer surgery - Mayo Clinic
Oct. 21, 2025
www.mayoclinic.org
November 4, 2025 at 3:03 PM
alcmi.bsky.social
Researchers at Cedars-Sinai Medical Center have published one of the most comprehensive national analyses to date on surgical timing for early-stage non-small cell lung cancer, using data from 219,723 patients in the National Cancer Database. #lungcancer
pubmed.ncbi.nlm.nih.gov/40950869/
Wait times between lung cancer diagnosis and surgery: national trends, disparities, and impact on long-term survival - PubMed
Wait times exceeding 4 weeks between lung cancer diagnosis and surgery for stage I and II NSCLC are increasingly common, particularly among non-Hispanic Black patients, and are associated with worse…
pubmed.ncbi.nlm.nih.gov
November 3, 2025 at 3:04 PM
alcmi.bsky.social
Hernexeos (zongertinib) has emerged as a treatment for first-line advanced HER2-mutated NSCLC with a 77% Objective Response Rate. #lungcancer
www.curetoday.com/view/hernexe...
Hernexeos Effective in HER2-Mutated NSCLC | CURE
The Beamion LUNG-1 study showed that first-line Hernexeos had benefit for patients with HER2-mutated NSCLC.
www.curetoday.com
November 2, 2025 at 3:01 PM
alcmi.bsky.social
Osimertinib retreatment may offer renewed disease control for select patients with advanced EGFR-mutated non-small cell lung cancer, according to new data from Fred Hutchinson Cancer Center. #lungcancer
www.sciencedirect.com/science/arti...
Osimertinib Retreatment for Patients with Advanced EGFR-mutated Non-Small Cell Lung Cancer
Further research is needed to identify biomarkers of sensitivity and to optimize patient selection for osimertinib retreatment following interval chemotherapy.
www.sciencedirect.com
November 1, 2025 at 2:02 PM
alcmi.bsky.social
Wow! Zocilurtatug pelitecan (ZL-1310), a next-generation DLL3-targeting antibody-drug conjugate, has demonstrated a 66% objective response rate in patients with extensive-stage small cell lung cancer and asymptomatic brain metastases. #lungcancer
www.aacr.org/about-the-aa...
Investigational Antibody-drug Conjugate Shows Clinical Benefit Against Previously Treated Small Cell Lung Cancer
BOSTON – Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the protein DLL3, demonstrated both safety and capacity to induce…
www.aacr.org
October 31, 2025 at 2:02 PM
alcmi.bsky.social
mRNA nanomedicines are moving beyond vaccines and emerging as a frontier in lung cancer treatment. #lungcancer
pubs.acs.org/doi/10.1021/...
Advancing Lung Cancer Treatment: mRNA Therapeutics and Delivery Strategies
Lung cancer tops the list of the deadliest malignancies, consistently resisting conventional therapies and fueling the urgent pursuit of novel treatment strategies. Messenger RNA (mRNA) nanomedicines…
pubs.acs.org
October 30, 2025 at 2:02 PM
alcmi.bsky.social
SystImmune and Bristol Myers Squibb have unveiled the first global Phase I results for iza-bren (BL-B01D1)—a potentially first-in-class EGFR x HER3 bispecific antibody-drug conjugate—presented at ESMO - European Society for Medical Oncology 2025 in Berlin. #lungcancer
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
Redmond, WA and Princeton, NJ – October 17, 2025 – SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of…
news.bms.com
October 28, 2025 at 2:05 PM
alcmi.bsky.social
Zongertinib has demonstrated unprecedented efficacy as a first-line treatment for HER2-mutant advanced lung cancer, with 96% disease control and complete tumor eradication in 8% of patients. #lungcancer
www.icr.ac.uk/about-us/icr...
New drug shows dramatic effect in shrinking lung cancer tumours
New drug shows dramatic effect in shrinking lung cancer tumours
www.icr.ac.uk
October 27, 2025 at 2:06 PM
alcmi.bsky.social
Anne Chiang, MD, PhD of Yale School of Medicine, recently spoke with Cancer Network about how a deeper understanding of tumor biology is transforming care for this historically intractable disease. #lungcancer
www.cancernetwork.com/view/leverag...
Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm | CancerNetwork
“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.
www.cancernetwork.com
October 26, 2025 at 2:02 PM
alcmi.bsky.social
COVID shots have been linked to longer lung cancer survival. #lungcancer
www.medpagetoday.com/meetingcover...
Cancer Study Links COVID Shots to Longer Survival
3-year survival twice as high with mRNA vaccine in lung cancer patients receiving immunotherapy
www.medpagetoday.com
October 25, 2025 at 2:02 PM
alcmi.bsky.social
Wow, big development! KEYTRUDA (pembrolizumab), developed by Merck, has now demonstrated sustained survival benefits up to 10 years for certain patients with non-small cell lung cancer. #lungcancer
www.merck.com/news/keytrud...
KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC) - Merck.com
Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before…
www.merck.com
October 24, 2025 at 2:04 PM
alcmi.bsky.social
Congratulations to our friends at Summit Therapeutics, Inc.! The company's joint project with AKESO has reported that their dual-acting antibody ivonescimab significantly delayed disease progression. #lungcancer
Summit’s dual-acting drug scores lung cancer win
A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study that could reshape first-line treatment regimens.
www.biopharmadive.com
October 23, 2025 at 2:03 PM
alcmi.bsky.social
Great interview with our friend Dr. Balazs Halmos, who sat down with Pharmacy Times to talk about findings from the PALOMA-3 trial. @lungcancer
www.pharmacytimes.com/view/subcuta...
Subcutaneous Amivantamab Shows Promise in EGFR-Mutated Lung Cancer | Pharmacy Times
Balazs Halmos, MD, discusses how the COPERNICUS trial aims to build on previous amivantamab studies.
www.pharmacytimes.com
October 22, 2025 at 2:06 PM
alcmi.bsky.social
Researchers at Yale School of Medicine and The University of Queensland have developed a spatial biology–driven “Google Maps” approach to predict how non-small cell lung cancer (NSCLC) responds to therapy. #lungcancer
medicine.yale.edu/news-article...
‘Google Maps’ Approach to Revolutionize Lung Cancer Treatment
The work provides a road map for new diagnostic tests that could optimize treatment choice.
medicine.yale.edu
October 21, 2025 at 2:05 PM
alcmi.bsky.social
Activating the NRF2E79Q mutation reshapes the differentiation trajectory of non-small cell lung cancer (NSCLC). Results were published in Cancer Gene Therapy (CGT). #lungcancer
www.nature.com/articles/s41...
Activating NRF2E79Q mutation alters the differentiation of human non-small cell lung cancer - Cancer Gene Therapy
Cancer Gene Therapy - Activating NRF2E79Q mutation alters the differentiation of human non-small cell lung cancer
www.nature.com
October 20, 2025 at 2:06 PM
alcmi.bsky.social
A global Phase 3 trial is underway to test ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, as a potential new standard for relapsed small cell lung cancer (SCLC). #lungcancer
www.tandfonline.com/doi/full/10....
IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer
IDeate-Lung02 will ascertain whether I-DXd treatment after only one prior line of systemic treatment improves outcomes for patients with relapsed SCLC compared with topotecan, amrubicin, or lurbinectedin.
www.tandfonline.com
October 19, 2025 at 2:01 PM
alcmi.bsky.social
AZD4625 study uncovers mTOR signaling as a key driver of primary resistance in KRAS-G12C NSCLC. #lungcancer
www.nature.com/articles/s41...
Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms - British Journal of Cancer
British Journal of Cancer - Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms
www.nature.com
October 18, 2025 at 2:03 PM
alcmi.bsky.social
Congratulations to Dr. Benjamin Levy and colleagues at Johns Hopkins Hospital! The phase 3 NeoADAURA study has established neoadjuvant osimertinib as a new benchmark for patients with resectable EGFR-mutated NSCLC, challenging the established standard of care. #lungcancer
Targeted Therapies Move the Needle in NSCLC | OncLive
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
www.onclive.com
October 17, 2025 at 2:05 PM
alcmi.bsky.social
Exciting research! Amivantamab plus lazertinib is the first targeted, chemotherapy-free regimen to show a survival advantage over osimertinib in frontline EGFR-mutated non-small cell lung cancer. #lungcancer
www.oncologynewscentral.com/nsclc/chemot...
Chemotherapy-Free Combo Prolongs Survival in EGFR-Mutated Non-Small Cell Lung Cancer
The findings were based on the final protocol-specified analysis of the phase 3 MARIPOSA trial.
www.oncologynewscentral.com
October 16, 2025 at 2:04 PM